Publications by authors named "Cinta Albacar"

Claim this Profile
O
Optimal [F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
Geraldine Gebhart, Marleen Keyaerts, Thomas Guiot, Patrick Flamen, Manuel Ruiz-Borrego, Cinta Albacar

J Nucl Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-year invasive disease-free survival with chemotherapy de-escalation using an F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, Marco Colleoni, Agostina Stradella, Cinta Albacar

Lancet· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life with palbociclib plus fulvestrant placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
Ariadna Tibau, M Teresa Martínez, Manuel Ramos, Luis De La Cruz-Merino, Ana Santaballa, Cinta Rosa Albacar

Ther Adv Med Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients.
Josep Gumà, Jose Adriá-Cebrián, Belen Ruiz-Aguado, Cinta Albacar, Josefa Girona

Cancers (Basel)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy de-escalation using an F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
José Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, Agostina Stradella, Begoña Bermejo, Cinta Albacar

Lancet Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Marta Rodríguez-Balada, Bàrbara Roig, Mireia Melé, Cinta Albacar, Sara Serrano

Clin Biochem· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis